Search 

Clinical Accelerator is an independent European clinical trial management organisation offering a range of clinical research and patient enrolment support services to worldwide clients in the pharmaceutical, biotechnology and medical device industries.

We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines.

Placing clinical trials in our Eastern European countries of operation allows Clinical Accelerator to achieve significant cost savings for our clients. Fast and large-scale patient recruitment is another important advantage. To ensure excellent quality of our Eastern European trials, we carefully select sites and investigators able to work to the highest quality standards with full ICH GCP compliance.

Clinical Accelerator provides client-tailored services. We are always prepared to adjust our system and procedures to the requirements of virtual, small and medium-sized biotech sponsors or larger pharma companies. We take a proactive role in the management of our projects based on intensive communication with our sponsors and joint commitment to success and always take responsibility for delivering clinical trials to agreed timeframes and within agreed budgets.

We deliver affordable clinical trials solutions with quality and speed!

We deliver solutions to optimize chemistry R&D innovation and efficiency, enabling our customers to accelerate the development of better treatments to improve the health of humans, animals and the environment.

Our intuitive software solutions are built on the combination of outstanding scientific rigor, ease-of-use and clear presentation of results scientists can rely on.

Our contract research solutions provide access to the deepest molecular modeling expertise in the industry.

Through provision of these agile offerings, we enable research chemists to make better molecule design and synthesis decisions. By unlocking new research insights and avenues, chemistry teams increase their chance of success in discovering new and better molecules.

Our proprietary platform selectively deliver drugs to damaged elastin. We already have proof of concept in cardiovascular calcification, aneurysms and emphysema animal models.

Erebagen is a synthetic biology company that discovers truly novel bioactive products from microbes by activating previously silent gene clusters 

There is a lot still to be discovered in microbial genomes and Erebagen is using its platform technology to discover new:

• Compounds The structurally diverse bioactive compounds produced by microbes that can act as fantiastic starting points in developing new drugs
• Chemistry How the biocatalysts involved on the production of metabolites work and how they can be used to perform unnatural reactions
• Control How biosynthetic pathways in microbes are controlled by regulators and how we can use these regulators to activate silent parts of the genomes

We are preparing a future round of fund raising and if you would like to hear about our eningeering platform, our buisness plan or how you could work with us please reach out to us

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

• 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
• GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
• Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
• GLP Analysis Certification and Problem Solving including GLP NMR 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

Evgen exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Established in 2001, Fusion Antibodies is a Collaborative Research Organisation (CRO) with its headquarters in Northern Ireland. We are world leaders in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics to clinical Cell Line Development.

We have guided hundreds of projects through critical pre-clinical stages, repeatedly proving our expertise as we strive to bring about a positive change in the healthcare industry.

Our approach to engineering and optimization is often to harness the power of the natural somatic hypermutation space. Fusion offers flexibility and agility while delivering clinical candidates focusing on developability, manufacturability and function.

Fusion has developed a number of unique, proprietary technology platforms. Our suite of development capabilities include:

• Antibody humanization (CDRx™)
• Affinity maturation (RAMP™)
• Protein engineering
• Discovery (mouse hybridoma and rabbit B cell approaches)
• Protein production – CHO and other mammalian systems
• Cell Line Development – cGMP ready mammalian cell lines (up to 8 g/L)
• Expert scientific & technical advisory services
• Bespoke & collaborative large-scale research and development programs

We are hVIVO plc (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials. We provide end-to-end early clinical development services for our broad and long-standing client base of global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.